Investors & Media

Habib Dable has served on our Board of Directors since June 2022. Mr. Dable is a versatile, patient-focused executive with approximately 28 years in “Big Pharma” and “Emerging Biotech” environments, currently a part-time Venture Partner at RA Capital Management, L.P. and an advisor for GLG Institute. Most recently, Mr. Dable was President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company targeting leading-edge therapies for patients with serious and rare diseases, until its acquisition by Merck in 2021 for $11.5B. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG. During his tenure at Bayer, Mr. Dable held positions of increasing responsibility, including President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA®; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. As Executive Vice President, Global Head Specialty Medicine, Mr. Dable led the launch of various blockbuster brands, including EYLEA®, STIVARGA®, and XOFIGO®. He currently serves on the Board of Directors of PepGen, Inc. Mr. Dable received a B.B.A. in marketing and finance and an M.B.A. from the University of New Brunswick.